In a cancer cell experiment, NVP-AUY922 was found to inhibit the NF-κB pathway to reduce the inflammatory response of cancer cells, indicating the anti-inflammatory potential of the drug (Walsby et al., 2013). Here, NFKB1 is linked to cancer.